Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

BAG-1 may predict survival in early breast cancer patients

Jairia Dela Cruz
07 Jul 2017

The co-chaperone protein B-cell lymphoma 2 (Bcl-2)-associated athanogene-1 (BAG-1) demonstrates prognostic value in early breast cancer, such that increased expression of BAG-1 mRNA and protein is associated with better outcomes, according to a systematic review and meta-analysis.

The analysis included 18 studies assessing the clinical significance of BAG-1 as a prognostic marker in breast cancer patients. BAG-1 mRNA expression was evaluated by methods including reverse transcription polymerase chain reaction (RT-PCR; two studies) and immunohistochemical staining (15 studies). Majority used full-face sections from formalin-fixed paraffin-embedded (FFPE) tumours (11 studies), whereas the remaining seven utilised FFPE tissue microarrays. [Br J Cancer 2017;116:1585–1594]

While data were too heterogeneous and outcome measures too varied to pool the results for majority of the studies, meta-analyses of mRNA expression from two studies involving a total of 2,422 patients yielded a hazard ratio (HR) of 0.55 (95 percent CI, 0.36 to 0.85), favouring improved breast cancer-specific survival (BCSS) with high expression of BAG-1.

Similarly, two studies involving 336 patients and evaluating pathologist assessment of nuclear BAG-1 found BCSS to improve with high BAG-1 levels (HR, 0.36; 0.23 to 0.55).

Finally, two studies that included 1,239 patients and investigated nuclear BAG-1 and distant disease-free survival reported improved outcomes with high BAG-1 expression (HR, 0.70; 0.59 to 0.84).

“The concept that BAG-1, a protein that supports cancer cell survival, is related to improved patient survival may seem paradoxical. This observation, however, is not without precedent as both the [oestrogen receptor (ER)] and Bcl-2, another antiapoptotic protein, [are] also associated with good prognosis in breast cancer,” the authors said, noting the increasing evidence supporting the hypothesis that BAG-1 plays an important role in breast cancer.

“The development of high-throughput assays, such as oncotype DX and PAM50, reveal that increased BAG-1 mRNA is associated with a low risk of recurrence and improved prognosis. In addition, a large RT-PCR study of a clinical trial cohort is also consistent with this,” they said. [Clin Cancer Res 2015;21:2763–2770]

The authors also cited recent data demonstrating that high nuclear BAG-1 immunoreactivity is an independent predictor of outcome, particularly in patients with ER+ early breast cancer receiving adjuvant hormonal therapy, and enhances the predictive power of IH4 staining. “Including BAG-1 immunohistochemical staining as a standard biomarker in the clinic may therefore help to better stratify patients according to their risk of disease recurrence and determine their probability of responding to therapy.”

They explained that the influence of BAG-1 on patient survival may be partly explained by the regulation of ER function, particularly at an early stage of the disease. [Cell Physiol Biochem 2014;33:365–374]

While the findings might be limited by the heterogeneity between studies, resulting in a considerable number of studies that could not be included in the analysis, the authors said the present review and meta-analyses “suggest that increased expression of BAG-1 mRNA and BAG-1 protein, and in particular nuclear expression, appears to be associated with improved breast cancer outcomes.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.